Skip to main content

Table 3 Urinary symptoms improvement after switching from tolterodine ER to fesoterodine according to age of patients

From: Dose and aging effect on patients reported treatment benefit switching from the first overactive bladder therapy with tolterodine ER to fesoterodine: post-hoc analysis from an observational and retrospective study

Urinary symptoms

(not at all = 0 to quite a lot = 5)

Total

<65 years

>65 years

P value between groups

r

Worry

     

 Frequency

3.2 (3.1-3.3)

3.2 (3.1-3.3)

3.3 (3.1-3.4)

0.325

0.056

 Incontinence during sexual attempt

2.2 (2.2-2.3)

2.3 (2.2-2.4)

2.0 (1.9-2.2)

0.008

−0.128

 Nocturia

3.0 (2.9-3.1)

3.0 (2.9-3.1)

3.1 (3.0-3.3)

0.051

0.104*

 Frequency of infections

2.4 (2.3-2.5)

2.4 (2.2-2.5)

2.4 (2.2-2.5)

0.923

0.022

 Urgency

3.2 (3.1-3.3)

3.2 (3.1-3.3)

3.3 (3.1-3.4)

0.585

0.044

 Bladder pain

2.3 (2.3-2.4)

2.3 (2.2-2.4)

2.4(2.2-2.5)

0.775

0.034

 Urge incontinence

3.1 (3.0-3.3)

3.1 (2.9-3.2)

3.2 (3.1-3.3)

0.211

0.055

 Urinary difficulties

2.2 (2.1-2.3)

2.1 (2.0-2.2)

2.3 (2.2-2.4)

0.070

0.141

 Stress incontinence

2.2 (2.1-2.3)

2.1 (2.0-2.2)

2.2 (2.1-2.4)

0.266

0.028

Bother

     

 Urinary frequency

3.2 (3.2-3.3)

3.2 (3.1-3.3)

3.3 (3.2-3.4)

0.453

0.029

 Strong desire to urinate

3.3 (3.2-3.4)

3.3 (3.1-3.4)

3.3 (3.2-3.4)

0.642

0.022

 Urine loss associated with a strong desire to urinate

3.1 (3.0-3.2)

3.1 (2.9-3.2)

3.2 (3.1-3.3)

0.117

0.055

Interference with daily-living activities

    

 Usual activities

3.0 (2.9-3.1)

3.0 (2.9-3.1)

3.1 (2.9-3.2)

0.519

0.034

 Leisure

3.1 (3.0-3.2)

3.1 (3.0-3.2)

3.1 (3.0-3.2)

0.761

−0.005

 Work/domestic activities

2.5 (2.4-2.6)

2.7 (2.6-2.8)

2.2 (2.0-2.3)

<0.001

−0.197

  1. p significance level adjusted by sex, driven of treatment change, treatment adherence, treatment length, reason for switching; Values are mean (95% Confidence Interval) Pearson coefficient of correlation between symptom score and age. *p < 0.05; ‡p ≤ 0.001.